{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:57:41Z","timestamp":1773946661199,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"vor","delay-in-days":364,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2018]]},"DOI":"10.6061\/clinics\/2018\/e510s","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T09:51:58Z","timestamp":1539683518000},"page":"e510s","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies"],"prefix":"10.1016","volume":"73","author":[{"given":"Victor Hugo Fonseca","family":"de Jesus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago Cordeiro","family":"Felismino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton Jos\u00e9","family":"de Barros e Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virg\u00edlio","family":"de Souza e Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel P","family":"Riechelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib1","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.6061\/clinics\/2018\/e510s_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/158038","article-title":"Immune Checkpoint Modulation in Colorectal Cancer: What\u2019s New and What to Expect","author":"Jacobs","year":"2015","journal-title":"J Immunol Res"},{"issue":"10053","key":"10.6061\/clinics\/2018\/e510s_bib3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"10.6061\/clinics\/2018\/e510s_bib4","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.3748\/wjg.v20.i14.3738","article-title":"Colorectal cancer and immunity: what we know and perspectives","volume":"20","author":"Pernot","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.6061\/clinics\/2018\/e510s_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12105","article-title":"Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy","volume":"1284","author":"Vesely","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.6061\/clinics\/2018\/e510s_bib6","first-page":"125","article-title":"Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives","volume":"11","author":"Zumwalt","year":"2015","journal-title":"Curr Colorectal Cancer Rep"},{"key":"10.6061\/clinics\/2018\/e510s_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4346576","article-title":"Immunotherapy in Gastrointestinal Cancers","volume":"2017","author":"Procaccio","year":"2017","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.6061\/clinics\/2018\/e510s_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc.2016.4","article-title":"Aspirin and colorectal cancer: the promise of precision chemoprevention","volume":"16","author":"Drew","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.6061\/clinics\/2018\/e510s_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2016.02.020","article-title":"Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives","volume":"59","author":"Moehler","year":"2016","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.6061\/clinics\/2018\/e510s_bib10","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.3748\/wjg.v23.i17.3017","article-title":"Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality","volume":"23","author":"Kourie","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2017.74.9846","article-title":"Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma","volume":"36","author":"Doi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.6061\/clinics\/2018\/e510s_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(17)30181-X","article-title":"Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial","volume":"18","author":"Kudo","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.6061\/clinics\/2018\/e510s_bib13","first-page":"300","article-title":"Adjuvant Beta-Interferon Therapy for Gastric Cancer. A Randomized Pilot Study","volume":"15","author":"Buhl","year":"1992","journal-title":"Onkologie"},{"issue":"4","key":"10.6061\/clinics\/2018\/e510s_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1634\/theoncologist.2-4-254","article-title":"New Advances in Interferon Therapy of Cancer","volume":"2","author":"Wadler","year":"1997","journal-title":"Oncologist"},{"issue":"9","key":"10.6061\/clinics\/2018\/e510s_bib15","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1349-7006.2003.tb01522.x","article-title":"Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide","volume":"94","author":"Sato","year":"2003","journal-title":"Cancer Sci"},{"issue":"9","key":"10.6061\/clinics\/2018\/e510s_bib16","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.21814","article-title":"An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study","volume":"106","author":"Ajani","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.6061\/clinics\/2018\/e510s_bib17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl.5","key":"10.6061\/clinics\/2018\/e510s_bib18","article-title":"KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G\/GEJ) cancer","volume":"28","author":"Wainberg","year":"2017","journal-title":"Ann Oncol"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib19","article-title":"KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer [abstract]","volume":"35","author":"Fuchs","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 4s","key":"10.6061\/clinics\/2018\/e510s_bib20","article-title":"Nivolumab \u00b1 ipilimumab in pts with advanced (adv)\/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study [abstract]","volume":"35","author":"Janjigian","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10111","key":"10.6061\/clinics\/2018\/e510s_bib21","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"6349","key":"10.6061\/clinics\/2018\/e510s_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib23","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity [abstract]","volume":"34","author":"Chung","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.6061\/clinics\/2018\/e510s_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase 3, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment for patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"issue":"10142","key":"10.6061\/clinics\/2018\/e510s_bib25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.6061\/clinics\/2018\/e510s_bib26","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.6061\/clinics\/2018\/e510s_bib27","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-17-0025","article-title":"Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced\/Metastatic Gastric or Gastroesophageal Junction Cancer","volume":"23","author":"Bang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.6061\/clinics\/2018\/e510s_bib28","author":"Genetics"},{"issue":"8","key":"10.6061\/clinics\/2018\/e510s_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e510s_bib30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MPA.0b013e31822ade7e","article-title":"An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer","volume":"41","author":"Gilliam","year":"2012","journal-title":"Pancreas"},{"issue":"12","key":"10.6061\/clinics\/2018\/e510s_bib31","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer","volume":"33","author":"Le","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2017.35.4_suppl.345","article-title":"Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study) [abstract]","volume":"35","author":"Le","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.6061\/clinics\/2018\/e510s_bib33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/bjc.2016.271","article-title":"Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer","volume":"115","author":"Dalgleish","year":"2016","journal-title":"Br J Cancer"},{"issue":"8","key":"10.6061\/clinics\/2018\/e510s_bib34","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"issue":"7","key":"10.6061\/clinics\/2018\/e510s_bib35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J Immunother"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib36","article-title":"Ipilimumab and gemcitabine for advanced pancreas cancer: A phase Ib study","volume":"34","author":"Kalyan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.6061\/clinics\/2018\/e510s_bib37","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.6061\/clinics\/2018\/e510s_bib38","article-title":"A Phase 1 Multi-arm Dose-expansion Study of the Anti-programmed Cell Death-ligand-1 (PD-L1) Antibody MEDI4736: Preliminary Data","volume":"25","author":"Segal","year":"2014","journal-title":"Ann Oncol"},{"issue":"4 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib39","doi-asserted-by":"crossref","first-page":"a412","DOI":"10.1200\/JCO.2017.35.4_suppl.412","article-title":"Phase I study of nivolumab (nivo) + nab-paclitaxel \u00b1 gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts [abstract]","volume":"35","author":"Wainberg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.6061\/clinics\/2018\/e510s_bib40","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/1078-0432.CCR-16-2318","article-title":"Strategies for Increasing Pancreatic Tumor Immunogenicity","volume":"23","author":"Johnson","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.6061\/clinics\/2018\/e510s_bib41","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"10.6061\/clinics\/2018\/e510s_bib42","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"issue":"10","key":"10.6061\/clinics\/2018\/e510s_bib43","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3748\/wjg.v23.i10.1899","article-title":"Microbiome and pancreatic cancer: A comprehensive topic review of literature","volume":"23","author":"Ertz-Archambault","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.510310111","article-title":"Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma","volume":"31","author":"Llovet","year":"2000","journal-title":"Hepatology"},{"issue":"3","key":"10.6061\/clinics\/2018\/e510s_bib45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.1840170307","article-title":"Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial","volume":"17","author":"Lai","year":"1993","journal-title":"Hepatology"},{"issue":"9","key":"10.6061\/clinics\/2018\/e510s_bib46","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/bjs.6731","article-title":"Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis","volume":"96","author":"Breitenstein","year":"2009","journal-title":"Br J Surg"},{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib47","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/SLA.0b013e3182363ff9","volume":"255","author":"Chen","year":"2012","journal-title":"Ann Surg"},{"issue":"9232","key":"10.6061\/clinics\/2018\/e510s_bib48","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial","volume":"356","author":"Takayama","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CJI.0b013e31815a121b","article-title":"Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas","volume":"31","author":"Weng","year":"2008","journal-title":"J Immunother"},{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.dld.2008.04.007","article-title":"A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma","volume":"41","author":"Hui","year":"2009","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.6061\/clinics\/2018\/e510s_bib51","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib53","article-title":"Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC) [abstract]","volume":"35","author":"Wainberg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10088","key":"10.6061\/clinics\/2018\/e510s_bib54","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.6061\/clinics\/2018\/e510s_bib55","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib56","article-title":"Phase I\/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses [abstract]","volume":"35","author":"Kelley","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.6061\/clinics\/2018\/e510s_bib57","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0959-8049(16)30326-4","article-title":"Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028","volume":"51","author":"Bang","year":"2015","journal-title":"Eur J Cancer"},{"issue":"26","key":"10.6061\/clinics\/2018\/e510s_bib58","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.6061\/clinics\/2018\/e510s_bib59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1758834016675803","article-title":"Refractory carcinoid syndrome: a review of treatment options","volume":"9","author":"Riechelmann","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl. 5","key":"10.6061\/clinics\/2018\/e510s_bib60","doi-asserted-by":"crossref","first-page":"v142","DOI":"10.1093\/annonc\/mdx368","article-title":"Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study [abstract]","volume":"28","author":"Mehnert","year":"2017","journal-title":"Ann Oncol"},{"key":"10.6061\/clinics\/2018\/e510s_bib61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ctrv.2017.04.002","article-title":"Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review","volume":"56","author":"Girardi","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib62","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13045-017-0511-2","article-title":"PD-1\/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy","volume":"10","author":"Long","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib63","article-title":"KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5- fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer [abstract]","volume":"35","author":"Bang","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.6061\/clinics\/2018\/e510s_bib64","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","article-title":"Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.6061\/clinics\/2018\/e510s_bib65","article-title":"Landscape of Microsatellite Instability Across 39 Cancer Types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"4 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib66","article-title":"PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers","volume":"34","author":"Le","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.6061\/clinics\/2018\/e510s_bib67","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1172\/JCI84940","article-title":"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J Clin Invest"},{"issue":"3","key":"10.6061\/clinics\/2018\/e510s_bib68","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10689-015-9803-2","article-title":"A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine","volume":"14","author":"Hansen","year":"2015","journal-title":"Fam Cancer"},{"issue":"5","key":"10.6061\/clinics\/2018\/e510s_bib69","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/21645515.2016.1269046","article-title":"Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials","volume":"13","author":"Catani","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"10.6061\/clinics\/2018\/e510s_bib70","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Pt 2","key":"10.6061\/clinics\/2018\/e510s_bib71","first-page":"29","article-title":"Emerging targets in cancer immunotherapy","volume":"52","author":"Burugu","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","article-title":"Prospects for gene-engineered T cell immunotherapy for solid cancers","volume":"22","author":"Klebanoff","year":"2016","journal-title":"Nat Med"},{"issue":"suppl 2","key":"10.6061\/clinics\/2018\/e510s_bib73","article-title":"Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed\/Refractory (R\/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis","volume":"17","author":"Buechner","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.6061\/clinics\/2018\/e510s_bib74","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib75","article-title":"Safety and antitumor activity of chimeric antigen receptor modified T Cells in patients with chemotherapy refractory metastatic pancreatic cancer [abstract]","volume":"33","author":"Beatty","year":"2015","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib76","article-title":"CD133-redirected chimeric antigen receptor engineered autologous T-cell treatment in patients with advanced and metastatic malignancies","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol [abstract]"},{"issue":"5","key":"10.6061\/clinics\/2018\/e510s_bib77","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/PAS.0b013e31820f18a2","article-title":"Clinicopathologic and molecular profiles of microsatellite unstable Barrett Esophagus-associated adenocarcinoma","volume":"35","author":"Farris","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.6061\/clinics\/2018\/e510s_bib78","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3892\/mco.2015.506","article-title":"Microsatellite instability and survival in gastric cancer: A systematic review and meta-analysis","volume":"3","author":"Zhu","year":"2015","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"10.6061\/clinics\/2018\/e510s_bib79","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2016.10.04","article-title":"Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency","volume":"5","author":"Silva","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"9","key":"10.6061\/clinics\/2018\/e510s_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046002","article-title":"Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma","volume":"7","author":"Laghi","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.6061\/clinics\/2018\/e510s_bib81","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.gastro.2016.09.060","article-title":"Hypermutation In Pancreatic Cancer","volume":"152","author":"Humphris","year":"2017","journal-title":"Gastroenterology"},{"issue":"8","key":"10.6061\/clinics\/2018\/e510s_bib82","first-page":"2536","article-title":"Prognostic value of microsatellite instability in resectable pancreatic cancer","volume":"8","author":"Nakata","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.6061\/clinics\/2018\/e510s_bib83","first-page":"3139","article-title":"Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability","volume":"61","author":"Yamamoto","year":"2001","journal-title":"Cancer Res"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2018\/e510s_bib84","article-title":"Microsatellite instability in pancreatic cancer","volume":"34","author":"Eatrides","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.6061\/clinics\/2018\/e510s_bib85","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/bjc.1998.124","article-title":"Molecular pathogenesis of sporadic duodenal cancer","volume":"77","author":"Achille","year":"1998","journal-title":"Br J Cancer"},{"issue":"11","key":"10.6061\/clinics\/2018\/e510s_bib86","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","article-title":"Genomic Profiling of Small-Bowel Adenocarcinoma","volume":"3","author":"Schrock","year":"2017","journal-title":"JAMA Oncol"},{"issue":"119","key":"10.6061\/clinics\/2018\/e510s_bib87","first-page":"2228","article-title":"Expression of hMLH1, hMSH2 and hMSH6 in small intestinal carcinomas","volume":"59","author":"Gu","year":"2012","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"10.6061\/clinics\/2018\/e510s_bib88","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1309\/AJCPGDDE8PLLDRCC","article-title":"DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases","volume":"133","author":"Agaram","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.6061\/clinics\/2018\/e510s_bib89","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/PAS.0b013e3181983ef7","article-title":"Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions","volume":"33","author":"Ruemmele","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e510s_bib90","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.celrep.2015.12.005","article-title":"Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation","volume":"14","author":"Gingras","year":"2016","journal-title":"Cell Rep"},{"issue":"3","key":"10.6061\/clinics\/2018\/e510s_bib91","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0168-8278(99)80047-6","article-title":"Microsatellite instability associated with hepatocarcinogenesis","volume":"31","author":"Kondo","year":"1999","journal-title":"J Hepatol"},{"issue":"4","key":"10.6061\/clinics\/2018\/e510s_bib92","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/carcin\/bgh035","article-title":"Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers","volume":"25","author":"Chiappini","year":"2004","journal-title":"Carcinogenesis"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:03:22Z","timestamp":1761721402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222011322"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322018000200333&lng=en&nrm=iso&tlng=en","label":"SCIELO"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/current-approaches-to-immunotherapy-in-noncolorectal-gastrointestinal-malignancies\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":92,"alternative-id":["S1807593222011322"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e510s","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2018\/e510s","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e510s"}}